價(jià)格 | ¥809 | ¥2195 |
包裝 | 5mg | 100mg |
最小起訂量 | 5mg |
發(fā)貨地 | 上海 |
更新日期 | 2023-10-16 |
中文名稱:PSI-7977,GS-7977,PSI 7977,GS 7977,sofosbuvir | 英文名稱:PSI-7977;GS-7977;PSI 7977;GS 7977;sofosbuvir |
CAS:1190307-88-0 | 純度規(guī)格: >98% |
產(chǎn)品類別: 激動(dòng)劑抑制劑 |
公告提醒:愛(ài)必信所有產(chǎn)品和服務(wù)僅用于科學(xué)研究,不用于臨床應(yīng)用及其他用途提供產(chǎn)品和服務(wù)(也不為任何個(gè)人提供產(chǎn)品和服務(wù))!
抑制劑描述:
產(chǎn)品名稱:PSI-7977
產(chǎn)品別名:索非布韋
英文別名:PSI-7977;GS-7977;PSI 7977;GS 7977;sofosbuvir
靶點(diǎn):NS5B polymerase
CAS:1190307-88-0
純度:>98%
外觀:Powder
保存方法:store at -20℃ for one year(Powder); in DMSO or others solvent store at 2-4℃ for two weeks, at -80℃ for six months.
描述:
PSI-7977 is an investigational nucleotide analog currently in Phase 2 for treatment of chronic HCV infection.
溶解性:DMSO:100 mg/mL warmed (188.87 mM)
Ethanol:100 mg/mL (188.87 mM)
Water:11 mg/mL warmed (20.77 mM)
體外研究:
As HCV NS5B polymerase inhibitor, PSI-7977 displays more potent inhibitory activity against HCV RNA replication than PSI-7976 with EC50 of 92 nM versus 1.07 μM and EC90 of 0.29 μM versus 2.99 μM, consistent with that incubating clone A cells with PSI-7977 leads to a higher concentration of PSI-7409 than clone A cells incubated with PSI-7976. PSI-7977 is an effective substrate for CatA to form PSI-352707 with 18-30 fold more potency as compared with PSI-7976. Unlike GS-7976, however, the CES1-mediated hydrolysis of PSI-7977 does not progress in a time-dependent manner. The S282T NS5B polymerase mutation but not S96T mutation confers resistance to PSI-7977 with EC90 increases from 0.42 μM to 7.8 μM. When assessed in an 8-day cytotoxicity assay, PSI-7977 displays no cytotoxicity against Huh7, HepG2, BxPC3, and CEM cells even at concentrations up to 100 μM. PSI-7977 treatment for 14 days shows a IC90 of 72.1 μM and 68.6 μM for the inhibition of mtDNA and rDNA, respectively, in HepG2 cells. PSI-7977 exhibits potent activity against genotype (GT) 1a, 1b, and 2a (strain JFH-1) replicons and chimeric replicons containing GT 2a (strain J6), 2b, and 3a NS5B polymerase. Sequence analysis of the JFH-1 NS5B region indicates that additional amino acid changes including T179A, M289L, I293L, M434T, and H479P are selected both prior to and after the emergence of S282T, which are required to confer resistance to PSI-7977.
體內(nèi)研究:
產(chǎn)品信息訂購(gòu):
產(chǎn)品更多信息請(qǐng)進(jìn)入愛(ài)必信網(wǎng)站咨詢
成立日期 | 2010-12-13 (15年) | 注冊(cè)資本 | 2500萬(wàn) |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1000萬(wàn)-5000萬(wàn) |
主營(yíng)行業(yè) | 生化試劑,抗體,分子生物學(xué),生物活性小分子 | 經(jīng)營(yíng)模式 | 工廠 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥15000 |
VIP12年
|
湖北威德利化學(xué)科技有限公司
|
2025-01-07 | |
詢價(jià) |
VIP5年
|
深圳菲斯生物科技有限公司
|
2025-01-07 | |
詢價(jià) |
VIP1年
|
普善實(shí)業(yè)(陜西)有限公司
|
2025-01-07 | |
詢價(jià) |
VIP10年
|
北京海步醫(yī)藥科技有限公司
|
2025-01-07 | |
詢價(jià) |
VIP2年
|
蘇州麗品化學(xué)有限公司
|
2025-01-07 | |
¥1358 |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-01-07 | |
詢價(jià) |
VIP5年
|
武漢鼎信通藥業(yè)有限公司
|
2025-01-07 | |
¥365 |
VIP4年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-01-07 | |
詢價(jià) |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-01-07 | |
¥12000 |
VIP9年
|
湖北威德利化學(xué)科技有限公司
|
2025-01-04 |